HPA axis and cytokines dysregulation in schizophrenia: Potential implications for the antipsychotic treatment

European Neuropsychopharmacology

Volumn 10, Issue 1, 1999, Pages 1-4

  Altamura, A Carlo ^a,b   Boin, Francesco ^a   Maes, Michael ^a,c  

^a UNIVERSITY OF MILAN   (Italy)

^b IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^c Stuivenberg General Hospital   (Belgium)

Author keywords

Atypical antipsychotics; Cytokines; Drug resistance; HPA axis; Negative symptoms; Schizophrenia

Indexed keywords

CLOZAPINE; HYDROCORTISONE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROLEPTIC AGENT;

ADRENAL SUPPRESSION; ARTICLE; CYTOKINE RELEASE; DRUG RESISTANCE; HIPPOCAMPUS; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERCHOLESTEROLEMIA; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; PRIORITY JOURNAL; SCHIZOPHRENIA;

ANIMALS; ANTIPSYCHOTIC AGENTS; CORTICOTROPIN-RELEASING HORMONE; CYTOKINES; DEXAMETHASONE; FEEDBACK; HUMANS; HYDROCORTISONE; HYPOTHALAMIC DISEASES; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; INFLAMMATION; PITUITARY-ADRENAL SYSTEM; RATS; SCHIZOPHRENIA; STRESS;

EID: 0032759229     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-977X(99)00017-6     Document Type: Article

References (44)

1. Addington D., Addington J. Depression dexamethasone nonsuppression and negative symptoms in schizophrenia. Can. J. Psychiatry. 35:(5):1990;430-433.
2. Altamura A.C. A multidimensional (pharmacokinetic and clinical-biological) approach to neuroleptic response in schizophrenia. With particular reference to drug resistance. Schizophr. Res. 8:(3):1992;187-198.
3. Altamura A.C. Hypothalamic-pituitary-adrenal axis in schizophrenia. Biol. Psychiatry. 40:(6):1996;560-561.
4. Altamura A.C. Novel antipsychotics and the problem of clinical stabilization in schizophrenia: are they 'stabilizer' rather than typical compounds? Int. Clin. Psychopharmacol. 11:1996;153-155.
5. Altamura C., Mauri M., Cavallaro R., Colacurcio F., Gorni A., Bareggi S. Reduced haloperidol/haloperidol ratio and clinical outcome in schizophrenia: preliminary evidences. Prog. Neuropsychopharmacol. Biol. Psychiatry. 12:(5):1988;689-694.
6. Altamura C., Guercetti G., Percudani M. Dexamethasone suppression test in positive and negative schizophrenia. Psychiatry Res. 30:(1):1989;69-75.
7. Barr C.E., Mednick S.A., Munk-Jorgensen P. Exposure to influenza epidemics during gestation and adult schizophrenia. A 40-year study. Arch. Gen. Psychiatry. 47:(9):1990;869-874.
8. Boyd J.H., Pulver A.E., Stewart W. Season of birth: schizophrenia and bipolar disorder. Schizophr. Bull. 12:(2):1986;173-186.
9. Bradbury T.N., Miller G.A. Season of birth in schizophrenia: a review of evidence, methodology, and etiology. Psychol. Bull. 98:(3):1985;569-594.
10. Carroll B.J., Feinberg M., Greden J.F., Tarika J., Albala A.A., Haskett R.F., James N.M., Kronfol Z., Lohr N., Steiner M., deVigne J.P., Young E. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch. Gen. Psychiatry. 38:(1):1981;15-22.
11. Coppen A., Abou-Saleh M., Milln P., Metcalfe M., Harwood J., Bailey J. Dexamethasone suppression test in depression and other psychiatric illness. Br. J. Psychiatry. 142:1983;498-504.
12. Coryell W., Tsuang D. Hypothalamic-pituitary-adrenal axis hyperactivity and psychosis: recovery during an 8-year follow-up. Am. J. Psychiatry. 149:(8):1992;1033-1039.
13. Farber N.B., Foster J., Duhan N.L., Olney J.W. Olanzapine and fluperlapine mimic clozapine in preventing MK-801 neurotoxicity. Schizophr. Res. 21:(1):1996;33-37.
14. Farber N.B., Newcomer J.W., Olney J.W. Glycine agonists: what can they teach us about schizophrenia? Arch. Gen. Psychiatry. 56:(1):1999;13-17.
15. Ismail K., Murray R.M., Wheeler M.J., O'Keane V. The dexamethasone suppression test in schizophrenia. Psychol. Med. 28:(2):1998;311-317.
16. Jansen L.M., Gispen-deWied C.C., Gademan P.J., DeJonge R.C., vanderLinden J.A., Kahn R.S. Blunted cortisol response to a psychosocial stressor in schizophrenia. Schizophr. Res. 33:(1-2):1998;87-94.
17. Jiang H.K., Wang J.Y. Diurnal melatonin and cortisol secretion profiles in medicated schizophrenic patients. J. Formos. Med. Assoc. 97:(12):1998;830-837.
18. Kunugi H., Nanko S., Takei N. Influenza and schizophrenia in Japan. Br. J. Psychiatry. 161:1992;274-275.
19. Lammers C.H., Garcia-Borreguero D., Schmider J., Gotthardt U., Dettling M., Holsboer F., Heuser I.J. Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II. Biol. Psychiatry. 38:(12):1995;803-807.
20. Lin A., Kenis G., Bignotti S., Tura G.J., De Jong R., Bosmans E., Pioli R., Altamura C., Scharpe S., Maes M. The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6. Schizophr. Res. 32:(1):1998;9-15.
21. Machon R.A., Mednick S.A., Huttunen M.O. Adult major affective disorder after prenatal exposure to an influenza epidemic. Arch Gen Psychiatry. 54:(4):1997;322-328.
22. Maes M., Bosmans E., Calabrese J., Smith R., Meltzer H.Y. Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 29:(2):1995;141-152.
23. Maes M., Bosmans E., Ranjan R., Vandoolaeghe E., Meltzer H.Y., DeLey M., Berghmans R., Stans G., Desnyder R. Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs. Schizophr. Res. 21:(1):1996;39-50.
24. Makino S., Smith M.A., Gold P.W. Increased expression of corticotropin-releasing hormone and vasopressin messenger ribonucleic acid (mRNA) in the hypothalamic paraventricular nucleus during repeated stress: association with reduction in glucocorticoid receptor mRNA levels. Endocrinology. 136:(8):1995;3299-3309.
25. Mauri M.C., Vita A., Giobbio G.M., Ferrara A., Dieci M., Bitetto A., Altamura A.C. Prediction of response to haloperidol in schizophrenia: neuroendocrine, neuromorphological and clinical variables. Int. Clin. Psychopharmacol. 9:(1):1994;3-7.
26. Mednick S.A. Schizophrenia: a viral disorder. Eur. Neuropsychopharmacol. 8:(S):1998;95.
27. Meltzer H.Y. Dopamine, serotonin and glucorticoids and the psychopathology of schizophrenia 1995. Fog R., Gerlach J. Schizophrenia: Alfred Bunsen Symposium 38 :1995;74-91 Munksgaard, Copenhagen.
28. Morgan V., Castle D., Page A., Fazio S., Gurrin L., Burton P., Montgomery P., Jablensky A. Influenza epidemics and incidence of schizophrenia, affective disorders and mental retardation in Western Australia: no evidence of a major effect. Schizophr. Res. 26:(1):1997;25-39.
29. Naudin J., Mege J.L., Azorin J.M., Dassa D. Elevated circulating levels of IL-6 in schizophrenia. Schizophr. Res. 20:(3):1996;269-273.
30. Nelson M.D., Saykin A.J., Flashman L.A., Riordan H.J. Hippocampal volume reduction in schizophrenia as assessed by magnetic resonance imaging: a meta-analytic study. Arch. Gen. Psychiatry. 55:(5):1998;433-440.
31. Newcomer J.W., Faustman W.O., Whiteford H.A., Moses J.A. Jr., Csernansky J.G. Symptomatology and cognitive impairment associate independently with post-dexamethasone cortisol concentrations in unmedicated schizophrenic patients. Biol. Psychiatry. 29:(9):1991;855-864.
32. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:(12):1995;998-1007.
33. Rantakallio P., Jones P., Moring J., VonWendt L. Association between central nervous system infections during childhood and adult onset schizophrenia and other psychoses: a 28-year follow-up. Int. J. Epidemiol. 26:(4):1997;837-843.
34. Rao M.L., Strebel B., Halaris A., Gross G., Braunig P., Huber G., Marler M. Circadian rhythm of vital signs, norepinephrine, epinephrine, thyroid hormones, and cortisol in schizophrenia. Psychiatry Res. 57:(1):1995;21-39.
35. Sapolsky R.M., Alberts S.C., Altmann J. Hypercortisolism associated with social subordinance or social isolation among wild baboons. Arch. Gen. Psychiatry. 54:(12):1997;1137-1143.
36. Selten J.P., Slaets J., Kahn R. Prenatal exposure to influenza and schizophrenia in Surinamese and Dutch Antillean immigrants to The Netherlands. Schizophr. Res. 30:(1):1998;101-103.
37. Sham P.C., O'Callaghan E., Takei N., Murray G.K., Hare E.H., Murray R.M. Schizophrenia following pre-natal exposure to influenza epidemics between 1939 and 1960. Br. J. Psychiatry. 160:1992;461-466.
38. Sharma R.P., Pandey G.N., Janicak P.G., Peterson J., Comaty J.E., Davis J.M. The effect of diagnosis and age on the DST: a metaanalytic approach. Biol. Psychiatry. 24:(5):1988;555-568.
39. Susser E., Lin S.P., Brown A.S., Lumey L.H., Erlenmeyer-Kimling L. No relation between risk of schizophrenia and prenatal exposure to influenza in Holland. Am. J. Psychiatry. 151:(6):1994;922-924.
40. Takei N., Mortensen P.B., Klaening U., Murray R.M., Sham P.C., O'Callaghan E., Munk-Jorgensen P. Relationship between in utero exposure to influenza epidemics and risk of schizophrenia in Denmark. Biol. Psychiatry. 40:(9):1996;817-824.
41. Tandon R., Mazzara C., DeQuardo J., Craig K.A., Meador-Woodruff J.H., Goldman R., Greden J.F. Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome. Biol. Psychiatry. 29:(10):1991;953-964.
42. Wang J., Dunn A.J. The role of interleukin-6 in the activation of the hypothalamo-pituitary-adrenocortical axis and brain indoleamines by endotoxin and interleukin-1 beta. Brain Res. 815:(2):1999;337-348.
43. Yeragani V.K. The incidence of abnormal dexamethasone suppression in schizophrenia: a review and a meta-analytic comparison with the incidence in normal controls. Can. J. Psychiatry. 35:(2):1990;128-132.
44. Yolken R.H., Torrey E.F. Viruses, schizophrenia, and bipolar disorder. Clin. Microbiol. Rev. 8:(1):1995;131-145.